Derma Innovate has developed compounds and a photodynamic therapy procedure to stimulate skin and capillary regeneration by activating local stem cells. They have had success in preclinical mouse trials and initial positive human clinical trials for applications like wound healing, hair growth, and burn recovery. Derma Innovate intends to license validated products in clinical and cosmetic areas, and has several lines of development around skin regeneration, capillary regeneration, veterinary applications, and a photodynamic therapy device.

1. DERMATOLOGY:
COMPOUND FOR
SKIN AND
CAPILLARY
REGENERATION
In cooperation with:

2. We have developed a series of compounds that regulate skin regeneration by locally
activating skin stem cells.
The process consists on an adapted
procedure of Photodynamic Therapy to
induce a temporary production of reactive
oxygen species, ROS in the tissue.
INNOVATIVE SOLUTION
CLINICAL AND COSMETICS AREAS OF APPLICATION – INTENDED AUDIENCE:
• Skin and hair regeneration
• Obtaining artificial skin of new generation
• In vitro hair regeneration
• Hair trasplant and alopecia treatments
• Obtaining therapies associated a photodynamic therapy device
• Animal Health
• Photodynamic Therapy Devices
Photodynamic Therapy (topical application of a photosensitive compound and subsequent
irradiation with the adequate light)
This new procedure has been successfully
tested in trials with mice and
in the first clinical trials in
humans.

3. Results obtained
INNOVATIVE SOLUTION
MICE HUMANS
Hair follicle
growth
activated
Burn healing
accelerated
Dr. Jesús Espada after several years of research at Harvard, at the CSIC and at the UAM and the team who constitute
the research group in Epithelial Biology and Dermatology Of the Ramón y Cajal Institute of Sanitary Research
(IRYCIS), whose head is Pedro Jaén Olasolo, have developed a new skin and capillary regeneration procedure
alongside Derma Innovate.
Background

4. BUSINESS MODEL
Discovering
phase
Development
of products
Clinical
Validation
Merchandising
phase
Our business model is based on licensing final products when they are
clinically validated.
Innovation Patents Clinical trials License

5. LINES OF DEVELOPMENT
The lines of development of Derma Innovate are:
1. SKIN REGENERATION: WOUNDS AND BURNS AND OBTAINING
ARTIFICIAL SKIN
Photosensitive compound of topical application associated with photodynamic
therapy (illumination with light of a suitable wavelength in the affected area).
This treatment activates the regeneration capacity of the cutaneous tissue.
Development phase:
• Preclinical phase successfully completed. Successful results.
• First positive results in clinical trials in humans.
2. CAPILLARY REGENERATION
Composition and procedure for topical application that allows to stimulate
regeneration and capillary growth.
Development phase:
• Preclinical phase successfully completed. Successful results.
• First positive results in clinical trials in humans.

6. LINES OF DEVELOPMENT
The lines of development of Derma Innovate are:
3. SKIN AND CAPILLARY REGENERATION IN VETERINARY (ANIMAL
HEALTH)
Topical compositions and photodynamic therapy procedure associated for the
stimulation and regeneration of cutaneous and capillary tissue (wounds, burns,
hair growth) in the veterinary area.
Development phase:
• Preclinical phase successfully completed. Successful results in mice.
4. PHOTODYNAMIC THERAPY DEVICE
Prototype of “user friendly” led lighting source applicable to human skin, with or
without hair, that allows the efective and direct stimulation of the tissue for its
regeneration, independently of any topical composition.
Development phase:
• Experimental phase.

7. PROJECT
LicenseProtected method by
patent
Clinical validation
CURRENT STATE: Clinical validation
Family: Use of a photosensitive agent capable of producing reactive oxygen species in the production of a drug for the
photodynamic therapy of a disease related to stem cells, in vitro use, and pharmaceutical composition
Country Status
Application
number
APPLICATION DATE
SPAIN Granted P201231759 14/11/2012
EUROPE Granted 13 855 732.7 11/11/2013
UNITED STATES Requested 14/442,876 11/11/2013
Family: Src kinase activators and Enf function inhibitors as enhancer of skin homeostasis/regeneration and hair growth
Country Status
Application
number
APPLICATION DATE
EUROPE
Favourable
patentability EP17382873 20/12/2017
PATENTS:

8. MARKET
POTENCIAL MARKET: Tissues engineering and regenerative medicine market
The global regenerative
medicine market was worth
$18.9 billion in 2016 and will
grow to over $53.7 billion by
2021, with a CAGR of 23.3%
between this time frame.
The global regenerative medicine
market in animals reached $ 5
billion in 2016. In 2021, it will
reach $ 6,1 billion with a
compound annual growth rate
(CAGR) of 4.06%.
Tissue-engineered skin substitutes market was valued at $1.3bn in 2017 and is expected to reach $2.3bn
by 2024, with a robust compound annual growth rate (CAGR) of 8.3%
Hair Loss & Growth Treatments and Products Market:
- Revenue is about $1.87 Billion in 2015.
- The global alopecia market is expected to reach over $11.8 Billion by 2024.
- In 2017, USA revenue of hair loss and growth treatments and products is nearly $931 millions, which
is 39.23% of global market.
Tissues engineering – Skin and Hair Growth:

9. MARKET
COMPETITORS. Examples of agreements in the cosmetic-phamaceutical market
Examples of movements in the regenerative medicine market
Company Quantity
Derma Sciences (regenerative medicine
for wound care) acquired the brand
MEDIHONEY, de Comvita Limited
13.25 million dollars
Integra LifeScience buys the company
Derma Sciences (advanced care of wounds
and burns)
204 million dollars
L'Oreal and Organovo (artificial leather
creation)
The companies will negotiate an
exclusive commercial supply
agreement that will include license
conditions and royalties (undisclosed
financial terms).
Smith & Nephew plans to acquire
Rotation Medical (regenerative tissue
medicine)
210 million dollars
Allergan buys the LifeCell unit of
regenerative medicine from Acelity
2,9 billion dollars
Aclaris therapeutics (compounds for
seborrheic dermatitis in advanced clinical
phase)
They raised 20 million dollars for all
their projects in 2014 in funding
rounds
Examples of license agreements in the hair regeneration market.
Agreement between: Agreed amount
RepliCel and Shisheido 4 million $ plus payments for
sales milestones of up to 30
million $
Rigel Pharmaceuticals and Aclaris
Therapeutics International Limited
8 million $ plus several
payments by stages and
royalties for future sales of up to
$ 90 million
Kythera Biopharmaceuticals and
Actelion Pharmaceuticals
27 million dollars
Cytori Therapeutics and Bimini
Technologies
15 million dollars
Haristetics and Italian venture
capital fund crossroad.
6 million dollars of financing

10. MARKET
COMPETITORS. Examples of agreements in the cosmetic-phamaceutical market
Examples of market movements in the field of animal regenerative
medicine
Companies Agreement/Data
Benchmark Holdings and Evax
AG
1.49 million dollars plus 5.3 million
dollars for the further development of
the product (treatment wounds in
horses)
Benchmark Holdings and
Saiba Pharmaceuticals
Vaccine for atopic dermatitis in dogs
(release in 2019)
Aratana Therapeutics and
Atopix Therapeutics
Canine dermatitis product license for 1
million dollars
Aratana Therapeutics, MPM
Capital and Avalon Ventures
20 million dollars of financing
According to the situation of the market, we are in a position to
say that our products, for all their characteristics, offer a great
attraction for companies in the clinical-cosmetic sector

11. OUR TEAM
Antonio Javier
Monis Ruiz
President
 Financial and
risk ex-director
in ING Seguros.
 Independent
advisor of
REALE VIDA.
Felipe Monis
Ruiz
Secretary
 Experience of 35
years as financial
adviser and asset
manager.
 AndBank Private
Banking
Consultant.
Enrique Sainz
Martínez
Advisor
 Co-founder of
“Valoralia I+D”.
 Co-founder of
several
consulting
companies in
R&D.
Juan José
Montoya
Miñano
Scientific Advisor
 Ex-Director of
the Fundation
Alfonso X el
Sabio University.
 Researcher in
Complutense
University of
Madrid.

12. OUR TEAM
Alfonso Ortega
Gallego
Advisor
 Technological
and
environmental
adviser.
 Wealth
Management.
Pedro Jaén
Olasolo
Scientific Advisor
 Head of the
Dermatology
Service of the
Hospital Ramón
y Cajal.
 President of the
Spanish
Academy of
Dermatology
and
Venereology.
 Owner of Pedro
Jaen’s Clinics.
Jesús Espada
Regalado
Advisor
 Main researcher
of project in
IRYCIS.
 Researcher at
Foundation for
Biomedical
Research of the
Hospital Ramón y
Cajal.
María
Inmaculada
Calvo Sánchez
Scientific Advisor
 Doctorate in
Celullar and
Genetic
Biology.
 Participation in
research
projects, such
as Homeostasis
and cutaneous
pathology.

13. OUR TEAM
Ramón Armengod
Corbella
Commercial/
Business area
 Head of sales
Biosurgery in Baxter.
 Commercial director
at Isdin.
Fernando Martínez
Morales
Commercial/
Business area
 Commercial director
at Astellas Pharma.
 Head of sales in
Astrazeneca
Pharmaceutical.
 Commercial ex-
director at Rovi
Laboratories.
María Isabel López
Ledesma
Commercial/Business
area
 Health visitor in
primary care and
specialists.
 Worked in the
commercial
department of both
companies and
banks (consultant /
sales manager).

14. FINANCIAL FORECAST
PROFIT AND LOSSES FORECAST (in thousands of euros)
2018 2019 2020 2021
Capillary growth license 11.287
Dermatology license 11.690
Veterinary license 5.240
Photodynamic therapy device 6.047
TOTAL LICENSES 0 11.287 16.930 6.047
Royalties receivable 1.129 2.822 3.426
TOTAL ROYALTIES RECEIVABLE 0 1.129 2.822 3.426
TOTAL LICENSES + ROYALTIES 0 12.416 19.752 9.473
TOTAL SUBSIDIES 150 100 100
TOTAL REVENUES 0 12.566 19.852 9.573
Commercial Expenses 364 438 309
Royalties payable 0 1.862 2.963 1.421
OPERATING MARGIN 0 10.339 16.452 7.843
Research Staff 90 125 126 128
Research Institute 173 165 165 165
Patents 34 40 40 40
General Expenses 84 85 86 87
TOTAL EXPENSES 381 414 417 419
PROFIT & LOSSES -381 9.925 16.035 7.423
CORPORATE TAX -57 1.432 2.405 1.856
NET PROFIT & LOSSES -324 8.494 13.630 5.567

15. FINANCIAL FORECAST
BALANCE SHEET FORECAST (in thousands of euros)
2018 2019 2020 2021
Intangible Assets 104 70 18 0
Equipment 1 0 0 0
Legal Reserve 811 1.363 742
Dividends 6.490 10.904 4.454
Cash and other liquid assets 17 1.244 1.848 874
TOTAL ASSETS 122 8.615 14.133 6.070
Stockholders’ equity 503 503 503 503
Benefit of the exercise -381 8.112 13.630 5.567
TOTAL LIABILITIES AND
STOCKHOLDERS' EQUITY
122 8.615 14.133 6.070

16. VALUATION OF THE COMPANY
Premoney Value Derma Innovate:
5,5 Millions € (aprox 1/6 Gross Profit of first 3 years)
Crowdfunding: 7 % of premoney value = 400.000 €
Pay-out policy = 80% over profit
Minimum
Investment
1.000 €
Contact telephone: 91 514 94 50
Account Number: ES15 2100 2351 1402 0036 7782

17. SUBSCRIPTION PROCEDURE
1. When the deposit is made by the contributor, an e-mail confirming
the deposit or transfer made and the number of shares acquired
will be sent.
2. At the end of the subscription period, the public deed of the capital
increase will be granted and the corresponding registration will be
made in the Commercial Registry.
3. Once the deed of the capital increase was registered in the
Commercial Registry, each partner was provided with a certificate
from the Commercial Registry in which his status as a partner was
accredited, meeting the requirements established by the Data
Protection General Regulation.
4. Periodically, the company will provide each partner with timely
information on the state of development of the research lines and
commerzialitation actions.

18. S C I E N C E T O M A R K E T
www.canaanrd.com
C/ Orense , 8
Oficinas - 1º planta,
28020 MADRID
+34 91 514 94 50
administracion@canaanrd.com
C/ Astrónoma Cecilia Payne
I.D 8.1. Edificio Centauro-
14014 CÓRDOBA